# Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer

> **NCT00620347** · PHASE2 · COMPLETED · sponsor: **National Cancer Center, Korea** · enrollment: 25 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** sunitinib

## Key facts

- **NCT ID:** NCT00620347
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2012-02
- **Final completion:** 2012-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00620347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00620347, "Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00620347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*